Form 4: DURECT CEO James Brown Granted Significant Restricted Stock Unit Award

DURECT Corporation's President and CEO, James E. Brown, was granted 96,959 shares of common stock through a restricted stock unit award, vesting on July 11, 2025.

Summary

• James E. Brown, who serves as President & CEO and a Director of DURECT Corporation (DRRX), acquired 96,959 shares of common stock.
• The acquisition was in the form of a time-based Restricted Stock Unit (RSU) award.
• The RSUs were granted at a price of $0 per share, which is typical for such awards.
• 100% of these RSUs are scheduled to vest on July 11, 2025, which marks the one-year anniversary of the grant date.
• Vesting is contingent upon James E. Brown's continued service with DURECT Corporation or any of its affiliates on the vesting date.
• Following this transaction, James E. Brown beneficially owns a total of 273,412 shares of DURECT Corporation common stock.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to the CEO is a positive indicator of continued executive alignment with shareholder interests and retention, reflecting a standard and beneficial compensation practice.

Positives

• The grant of Restricted Stock Units to the CEO aligns management's long-term interests with those of shareholders, as the value of the award is tied to the company's stock performance.
• This RSU award indicates continued commitment and retention of a key executive, James E. Brown, to DURECT Corporation.

Risks

• The vesting of the 96,959 Restricted Stock Units is subject to James E. Brown's continued service with the company until July 11, 2025, meaning the shares could be forfeited if his service ceases before that date.

Future Outlook

The 96,959 Restricted Stock Units are scheduled to vest on July 11, 2025, contingent on the CEO's continued service with the company.

Industry Context

Restricted Stock Unit grants are a common and widely accepted form of executive compensation across various industries, including biotechnology and pharmaceuticals. This practice is designed to align the incentives of company leadership with the long-term performance and shareholder value creation, reflecting a standard approach to executive retention and motivation within the sector.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of executive compensation is a standard practice across the biotechnology and pharmaceutical industries, comparable to compensation structures seen in companies like Gilead Sciences, Amgen, or Biogen, which frequently utilize equity awards to incentivize long-term performance.
• The grant of RSUs at a $0 price is typical for such awards, as they represent a right to receive shares upon vesting, rather than a purchase.

Related Party Transactions

• The RSU grant to James E. Brown, the President & CEO and a Director, constitutes a related party transaction, which is a common and disclosed practice for executive compensation.

Stakeholder Impact

• Shareholders: The RSU grant aligns the CEO's financial interests with the long-term performance of the company, potentially encouraging decisions that enhance shareholder value.
• Employees: May signal stability in leadership and a commitment to executive retention, which can positively influence employee morale and confidence.

Next Steps

• The 96,959 Restricted Stock Units are expected to vest on July 11, 2025, provided James E. Brown remains in service with DURECT Corporation.

Key Dates

Keywords

DURECT Corporation, DRRX, James E. Brown, Restricted Stock Units, RSU, executive compensation, insider transaction, stock grant, SEC Form 4